Pinworm and TNKS inhibitors, an eccentric duo to derail the oncogenic WNT pathway

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• The WNT/β-catenin pathway is frequently dysregulated in human cancers due to mutations in key genes like APC, β-catenin, and Axin.
• Aberrant WNT signaling activation, often involving glycogen synthase kinase 3β (GSK3β) localization, leads to β-catenin accumulation and oncogene-driven cell proliferation.
• Understanding the molecular homeostasis and developing targeted inhibitors are critical for cancer therapy.

Purpose of the Study:

• To explore the role of the WNT/β-catenin pathway in human cancers.
• To review recent advancements in identifying novel small-molecule WNT inhibitors.
• To discuss the potential of these inhibitors and associated biomarkers for cancer treatment.

Main Methods:

• Review of current literature on WNT pathway signaling in cancer.
• Analysis of novel small-targeted inhibitors and their mechanisms of action.
• Investigation into the regulation of β-catenin degradation and WNT pathway homeostasis.

Main Results:

• Mutations in APC, β-catenin, and Axin genes activate the WNT pathway in various cancers.
• GSK3β mislocalization prevents β-catenin degradation, promoting cancer cell proliferation.
• Novel inhibitors targeting tankyrases and casein kinase 1α/γ show potential for WNT pathway modulation.

Conclusions:

• The WNT/β-catenin pathway is a significant driver in numerous human cancers.
• Targeting specific enzymes involved in β-catenin regulation presents a viable therapeutic strategy.
• Further research may identify new biomarkers and effective WNT-targeted cancer therapies.